Equities

Anteris Technologies Ltd

Anteris Technologies Ltd

Actions
Health CareMedical Equipment and Services
  • Price (AUD)18.90
  • Today's Change-0.33 / -1.72%
  • Shares traded6.23k
  • 1 Year change-21.25%
  • Beta0.6480
Data delayed at least 20 minutes, as of May 23 2024 05:50 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Anteris Technologies Ltd is an Australia-based structural heart company. The Company is engaged in designing, developing, and commercializing medical devices. The Company’s lead product, DurAVR, is a transcatheter heart valve (THV) for treating aortic stenosis. DurAVR THV is made using ADAPT tissue, its patented anti-calcification tissue technology. DurAVR THV is a novel first-in-class biomimetic valve made from a single piece of native-shaped tissue. It is designed to mimic the performance of a pre-disease human aortic valve. Its balloon expandable ComASUR Delivery System provides controlled deployment and accurate placement of the DurAVR THV valve, designed to achieve precise alignment with the heart’s native commissures to achieve ideal valve positioning.

  • Revenue in AUD (TTM)7.03m
  • Net income in AUD-67.33m
  • Incorporated1999
  • Employees1.00
  • Location
    Anteris Technologies LtdTOOWONG TOWERSUITE 302, LEVEL 3, 9 SHERWOOD RDTOOWONG 4066AustraliaAUS
  • Phone+61 30055-0310
  • Fax+61 30088-0398
  • Websitehttps://anteristech.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Imricor Medical Systems Inc923.31k-33.94m90.14m--------97.62-0.2156-0.21560.0059-0.07770.05590.87492.38---205.60-93.47-294.49-106.30-181.27-134.71-3,675.60-2,462.890.4944-3.6415.92---24.56-9.29-30.36---10.82--
SDI Ltd109.61m8.04m93.31m300.0011.611.057.560.85130.06760.06760.92210.74940.84491.696.22--6.207.277.468.4059.2859.797.348.071.2610.370.231851.8513.357.67-3.094.5052.585.39
Genetic Signatures Ltd16.49m-18.04m139.89m----3.45--8.48-0.1245-0.12450.11360.21720.33661.065.25---36.81-7.14-40.19-7.8240.6657.68-109.38-13.745.95-18,040.000.0003---38.1133.44-558.77--73.20--
Cyclopharm Limited32.21m-4.70m146.94m87.00--4.55--4.56-0.0508-0.05080.34760.34280.67481.114.13370,173.10-9.85-12.60-11.92-14.9468.1570.20-14.60-25.472.32-18.400.1159--11.2215.5028.90---7.83-12.94
Mach7 Technologies Ltd26.97m-5.55m160.43m90.00--2.9574.125.95-0.0231-0.02310.11230.22560.3605--3.21---7.42-7.48-8.73-8.6595.0993.72-20.59-20.56---2,605.170.0193--10.9728.3074.85--29.28--
EMvision Medical Devices Ltd8.86m-3.22m164.44m----26.28--18.56-0.0449-0.04490.11860.07330.7954-------28.95-67.20-45.25-79.38-----36.40-175.99---35.200.3424--62.0870.4736.64------
Aroa Biosurgery Ltd60.34m-7.59m170.38m261.00--1.91--2.82-0.0221-0.02210.17580.2590.57641.693.18231,186.50-7.25-9.60-7.88-12.0884.4777.32-12.58-18.987.09-12.520.065--59.6841.6895.28--35.28--
ImpediMed Ltd10.47m-19.42m171.96m76.00--3.37--16.42-0.0102-0.01020.00550.02520.19611.324.41137,802.60-36.37-52.27-40.94-62.3486.9580.64-185.47-264.766.85--0.0244--7.3627.87-3.26--37.83--
4DMedical Ltd1.03m-30.83m227.01m----2.49--221.42-0.0882-0.08820.00290.23320.00980.0920.1585---29.47-43.96-39.07-57.5895.0032.30-3,007.64-2,704.361.79--0.0476---31.84-1.86-27.92--2.46--
Paragon Care Ltd.317.39m10.31m247.11m0.0024.230.984411.200.77860.01530.01240.46980.37590.68063.008.84--2.54-1.783.32-2.3340.9239.553.73-2.580.71213.040.374--29.5521.27111.05-1.5426.29-17.29
EBR Systems Inc0.00-52.55m351.22m----7.51-----0.1814-0.18140.000.15170.00-------46.54---50.70-------------28.660.5609-------5.89------
Anteris Technologies Ltd7.03m-67.33m380.79m1.00--12.34--54.18-4.30-4.300.45031.610.20322.726.69---199.17-120.86-288.53-189.2777.3266.40-980.31-316.852.55-52.000.0804--4.48-22.85-51.86--42.27--
Nanosonics Ltd.164.07m15.68m878.64m482.0056.715.0038.245.360.05110.05110.53540.57970.76561.294.93340,385.907.327.088.478.1679.0776.919.569.755.55--0.05720.0037.9622.29431.3528.164.83--
Data as of May 23 2024. Currency figures normalised to Anteris Technologies Ltd's reporting currency: Australian Dollar AUD

Institutional shareholders

34.48%Per cent of shares held by top holders
HolderShares% Held
L1 Capital Pty Ltd.as of 02 Jan 20242.84m14.80%
Perceptive Advisors LLCas of 02 Nov 20232.14m11.14%
Sio Capital Management LLCas of 01 Nov 20231.03m5.38%
Mutual Trust Pty Ltd.as of 27 Mar 2023335.69k1.75%
Rhenman & Partners Asset Management ABas of 30 Jun 2023268.76k1.40%
Fideuram Asset Management (Ireland) DACas of 29 Apr 20244.00k0.02%
Bartlett & Co. Wealth Management LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 29 Apr 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.